NewsDialy
Chemed (CHE) shares have climbed to $493.23, marking a 26.2% increase over the past six months. This performance has allowed the stock to outperform the S&P 500 by 11.9%.
Despite this recent momentum, analysts at StockStory express limited confidence in the company's long-term business quality, citing specific weaknesses in sales growth and profitability trends.
The primary concern centers on Chemed's revenue trajectory. Over the last five years, the company's sales grew at a compounded annual growth rate of 4.1%.
Analysts describe this pace as mediocre, noting it falls below their standard for the healthcare sector.
Keep reading